Literature DB >> 19721845

Effects of overnight sleep restriction on brain chemistry and mood in women with unipolar depression and healthy controls.

Denise Bernier1, Robert Bartha, Sivakumaran Devarajan, Frank P Macmaster, Matthias H Schmidt, Benjamin Rusak.   

Abstract

BACKGROUND: Partial or total overnight sleep deprivation produces immediate mood improvement in about 50% of patients with depression, but not in healthy controls. Our objectives were to compare the neurochemical changes that accompanied partial overnight sleep deprivation in healthy and depressed participants, and to compare baseline neurochemical profiles and overnight neurochemical changes between those depressed participants who did and did not respond to sleep loss with mood improvement.
METHODS: We studied 2 brain regions (left dorsal prefrontal area and pons) in 12 women with unipolar depression and in 15 healthy women using proton magnetic resonance spectroscopy acquired at 1.5 T. The scans took place at baseline and 24 hours later after a night with sleep restricted to a maximum of 2.5 hours (22:30-01:00). We assessed 3 neurochemical signals (referenced to internal water): N-acetylaspartate (NAA), choline compounds (Cho) and creatine-plus-phosphocreatine (tCr).
RESULTS: In both groups combined, sleep restriction caused a 20.1% decrease in pontine tCr (F(1-16) = 5.07, p = 0.039, Cohen's d = 0.54) and an 11.3% increase in prefrontal Cho (F(1-21) = 5.24, p = 0.033, Cohen's d = 0.46). Follow-up tests revealed that prefrontal Cho increases were significant only among depressed participants (17.9% increase, t(9) = -3.35, p = 0.008, Cohen's d = 1.06). Five depressed patients showed at least 30% improvement in mood, whereas 6 showed no change or worsening in mood after sleep restriction. Baseline pontine Cho levels distinguished subsequent responders from nonresponders to sleep restriction among depressed participants (z = 2.61, p = 0.008). LIMITATIONS: A limitation of this study is the relatively small sample size.
CONCLUSION: Sleep restriction altered levels of pontine tCr and prefrontal Cho in both groups combined, suggesting effects on phospholipid and creatine metabolism. Baseline levels of pontine Cho were linked to subsequent mood responses to sleep loss, suggesting a role for pontine phospholipid metabolism in mood effects of sleep restriction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19721845      PMCID: PMC2732741     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  32 in total

1.  Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction.

Authors:  R Bartha; D J Drost; R S Menon; P C Williamson
Journal:  Magn Reson Med       Date:  2000-10       Impact factor: 4.668

2.  Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism.

Authors:  Wayne C Drevets; Wendy Bogers; Marcus E Raichle
Journal:  Eur Neuropsychopharmacol       Date:  2002-12       Impact factor: 4.600

Review 3.  Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression.

Authors:  W C Drevets
Journal:  Prog Brain Res       Date:  2000       Impact factor: 2.453

Review 4.  Role of norepinephrine in the pathophysiology and treatment of mood disorders.

Authors:  K J Ressler; C B Nemeroff
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

5.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response.

Authors:  H S Mayberg; S K Brannan; J L Tekell; J A Silva; R K Mahurin; S McGinnis; P A Jerabek
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

6.  Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression.

Authors:  S H Kennedy; K R Evans; S Krüger; H S Mayberg; J H Meyer; S McCann; A I Arifuzzman; S Houle; F J Vaccarino
Journal:  Am J Psychiatry       Date:  2001-06       Impact factor: 18.112

7.  Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity.

Authors:  M Thomas; H Sing; G Belenky; H Holcomb; H Mayberg; R Dannals; H Wagner; D Thorne; K Popp; L Rowland; A Welsh; S Balwinski; D Redmond
Journal:  J Sleep Res       Date:  2000-12       Impact factor: 3.981

8.  Increase in amino acids in the pons after sleep deprivation: a pilot study using proton magnetic resonance spectroscopy.

Authors:  Harald Murck; Tobias Struttmann; Michael Czisch; Thomas Wetter; Axel Steiger; Dorothee P Auer
Journal:  Neuropsychobiology       Date:  2002       Impact factor: 2.328

9.  The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression - an MR spectroscopy study.

Authors:  Harald Murck; Mirjam I Schubert; Dagmar Schmid; Petra Schüssler; Axel Steiger; Dorothee P Auer
Journal:  J Psychiatr Res       Date:  2008-06-03       Impact factor: 4.791

10.  Energy consumption by phospholipid metabolism in mammalian brain.

Authors:  A D Purdon; T A Rosenberger; H U Shetty; S I Rapoport
Journal:  Neurochem Res       Date:  2002-12       Impact factor: 3.996

View more
  9 in total

1.  Self-reported sleep correlates with prefrontal-amygdala functional connectivity and emotional functioning.

Authors:  William D S Killgore
Journal:  Sleep       Date:  2013-11-01       Impact factor: 5.849

Review 2.  Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature.

Authors:  Eduardo Caverzasi; Anna Pichiecchio; Guy Umberto Poloni; Alessandro Calligaro; Moreno Pasin; Fulvia Palesi; Gloria Castellazzi; Massimo Pasquini; Massimo Biondi; Francesco Barale; Stefano Bastianello
Journal:  Funct Neurol       Date:  2012 Jan-Mar

3.  Sleep patterns and the risk for unipolar depression: a review.

Authors:  Sabrina T Wiebe; Jamie Cassoff; Reut Gruber
Journal:  Nat Sci Sleep       Date:  2012-05-29

4.  A MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs.

Authors:  Yifan Zhang; Yu Han; Yongzhi Wang; Yinfeng Zhang; Li Li; Erhu Jin; Ligang Deng; Brandi Watts; Teresa Golden; Ning Wu
Journal:  BMC Psychiatry       Date:  2015-05-02       Impact factor: 3.630

5.  NPAS3 variants in schizophrenia: a neuroimaging study.

Authors:  Denise Bernier; Georgina Macintyre; Robert Bartha; Christopher C Hanstock; David McAllindon; Diane Cox; Scot Purdon; Katherine J Aitchison; Benjamin Rusak; Philip G Tibbo
Journal:  BMC Med Genet       Date:  2014-03-27       Impact factor: 2.103

6.  Lower Choline-Containing Metabolites/Creatine (Cr) Rise and Failure to Sustain NAA/Cr Levels in the Dorsolateral Prefrontal Cortex Are Associated with Depressive Episode Recurrence under Maintenance Therapy: A Proton Magnetic Resonance Spectroscopy Retrospective Cohort Study.

Authors:  Neven Henigsberg; Helena Šarac; Marko Radoš; Milan Radoš; David Ozretić; Tamara Foro; Viktorija Erdeljić Turk; Pero Hrabač; Maja Bajs Janović; Benedict Rak; Petra Kalember
Journal:  Front Psychiatry       Date:  2017-12-13       Impact factor: 4.157

7.  Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study.

Authors:  Neven Henigsberg; Aleksandar Savić; Marko Radoš; Milan Radoš; Helena Šarac; Ana Šečić; Maja Bajs Janović; Tamara Foro; David Ozretić; Viktorija Erdeljić Turk; Pero Hrabač; Petra Kalember
Journal:  Psychopharmacology (Berl)       Date:  2019-09-04       Impact factor: 4.530

Review 8.  Relapse prediction: A meteorology-inspired mobile model.

Authors:  F Michler Bishop
Journal:  Health Psychol Open       Date:  2016-09-04

9.  The effect of sleep deprivation and restriction on mood, emotion, and emotion regulation: three meta-analyses in one.

Authors:  Cara C Tomaso; Anna B Johnson; Timothy D Nelson
Journal:  Sleep       Date:  2021-06-11       Impact factor: 5.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.